Does Anthem (Elevance Health) Cover Saxenda for Weight Loss?

How Anthem (Elevance Health) Classifies Saxenda

Anthem treats Saxenda as a specialty weight-management drug, not a standard chronic-disease medication. Most Anthem commercial PPO and HMO formularies place liraglutide 3 mg on Tier 3 (preferred brand) or Tier 4 (non-preferred specialty), depending on the specific plan document, state market, and plan year. A small number of fully-insured large-group plans exclude anti-obesity medications entirely under a blanket carve-out, which means no amount of step therapy or documentation will produce coverage without a plan amendment.

Saxenda received FDA approval in December 2014 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. [1] The active ingredient, liraglutide 3 mg injected subcutaneously once daily, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is distinct from liraglutide 1.2 or 1.8 mg (Victoza), which Anthem covers under a separate diabetes formulary pathway.

Because Anthem's formulary decisions are made at the plan-document level rather than centrally, members should pull their current Summary of Benefits and Coverage (SBC) and the full formulary PDF from anthem.com before assuming coverage applies.

Prior Authorization Criteria for Saxenda on Anthem

Getting prior authorization (PA) approved is the single biggest barrier. Anthem's medical policy for anti-obesity agents typically requires all of the following before a PA will be granted.

BMI threshold. A documented BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one qualifying comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, or dyslipidemia), must appear in the medical record within the prior 12 months. [2]

Documented behavioral program participation. Most Anthem PA policies require proof of enrollment in, or completion of, a structured weight-loss program lasting at least 3 to 6 months. "Structured" generally means supervised dietary counseling, caloric targets, and physical activity goals recorded by a clinician or registered dietitian. A printout from a consumer app is not sufficient.

Prescriber specialty or training attestation. Some Anthem plans require the prescriber to attest that they have reviewed contraindications, including the boxed warning for thyroid C-cell tumors in rodents and the drug's contraindication in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. [1]

No contraindicated condition. Pregnancy, prior serious hypersensitivity to liraglutide, and active pancreatitis are absolute contraindications per the FDA label and are cited verbatim in most Anthem PA criteria documents. [1]

Standard PA requests receive a decision within 3 to 15 business days. Urgent or expedited requests, when a delay could seriously jeopardize health, must receive a decision within 72 hours under federal Utilization Review Accreditation Commission (URAC) and state insurance code standards.

The HealthRX clinical team has consolidated Anthem's published PA checklists and member-appeal data into a single submission framework. Before the prescriber submits the PA request, the chart note should document (1) current weight and height with BMI calculated, (2) the qualifying comorbidity with ICD-10 code, (3) the name and duration of the behavioral weight-loss program, (4) any prior pharmacotherapy trials and outcomes, and (5) the prescriber's review of contraindications. Submitting all five elements in the first PA request reduces the median time to approval and decreases the rate of administrative denials by removing "missing information" as a denial reason.

Step Therapy: Which Drugs Must Be Tried First?

Anthem's step therapy protocol for anti-obesity medications most commonly requires a documented trial of at least one prior weight-loss agent before Saxenda will be authorized. The specific agents accepted as step-one drugs vary by plan document, but phentermine/topiramate extended-release (Qsymia), orlistat (Xenical/Alli), phentermine monotherapy, or bupropion/naltrexone (Contrave) appear most frequently on Anthem's accepted step-one lists.

The trial must be documented in the prescriber's chart notes, not simply self-reported by the patient. Anthem typically requires at least 90 days of step-one therapy at an adequate dose with recorded body weight at baseline and at follow-up. If the patient lost less than 5% of baseline body weight or experienced intolerable side effects, the chart must document that outcome explicitly.

Step therapy exemptions are possible. Under many state step-therapy reform laws (including laws in California, Texas, New York, Illinois, and more than 30 other states), a prescriber can request an exemption from step therapy if the required drug is contraindicated, previously tried and failed, or would cause an adverse reaction. The prescriber's attestation letter invoking a state step-therapy exemption law must reference the relevant statute to be effective.

The SCALE Obesity and Prediabetes trial (N=3,731) published in the New England Journal of Medicine in 2015 showed that liraglutide 3 mg produced a mean body weight loss of 8.0% at 56 weeks compared to 2.6% with placebo (P<0.001), and 63.2% of liraglutide-treated patients lost at least 5% of body weight versus 27.1% with placebo. [3] That efficacy data can be cited in a step-therapy exemption letter to argue that substituting an inferior agent first is clinically unreasonable for a given patient profile.

What Anthem's Formulary Tier Means for Your Out-of-Pocket Cost

Tier placement directly controls cost-sharing. On a typical Anthem PPO with a $4,000 individual deductible:

• Tier 3 preferred brand. After deductible, copays commonly run $60 to $100 per 30-day supply.
• Tier 4 non-preferred specialty. After deductible, coinsurance of 30% to 40% applies. At list price ($1,349/month), that equals $405 to $540 out of pocket per month after the deductible is met.

Anthem plans subject to the ACA's preventive-services mandate may cover obesity counseling at no cost-sharing, but the mandate does not require coverage of anti-obesity drugs. The U.S. Preventive Services Task Force gives intensive behavioral counseling for obesity a Grade B recommendation for adults with BMI ≥30. [4] That counseling coverage is separate from drug coverage.

Some Anthem Medicaid plans (branded as Anthem BlueCross BlueShield Medicaid or similar) exclude Saxenda entirely because state Medicaid formularies in several states do not list anti-obesity drugs. Members on Anthem Medicaid should contact their state Medicaid office directly.

How to Appeal a Denial of Saxenda Coverage

Anthem denials arrive as an Explanation of Benefits (EOB) or a written denial letter specifying the reason. The three most common denial reasons for Saxenda are (1) missing PA criteria documentation, (2) step therapy not completed, and (3) benefit exclusion for anti-obesity drugs.

Level 1: Anthem Internal Appeal. The member or prescriber has 180 days from the denial date to file a Level 1 internal appeal. The prescriber should submit a letter of medical necessity that directly responds to the stated denial reason, attaches peer-reviewed clinical evidence, and cites the FDA label indication. [1] The SCALE trial data showing 63.2% of patients achieving ≥5% weight loss versus 27.1% with placebo [3] is directly relevant for medical-necessity appeals.

The American Association of Clinical Endocrinology (AACE) 2023 Obesity Guidelines state: "Anti-obesity medications are indicated as an adjunct to intensive behavioral therapy in patients with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related complications." [5] Quoting this directly in an appeal letter anchors the request to a named clinical guideline, which Anthem's appeals reviewers must address on the merits.

Level 2: External Independent Review. If the Level 1 appeal is denied, members have the right to an Independent Review Organization (IRO) review under state law and the ACA. The IRO is a neutral third party. IRO decisions are binding on the insurer in most states. For Anthem members, the state Department of Insurance typically assigns the IRO. The member does not pay for the IRO review.

Expedited appeal. When a delay in treatment would cause imminent and serious harm, an expedited appeal must be decided within 72 hours. Severe obesity with documented cardiovascular risk factors or active non-alcoholic steatohepatitis could support an expedited appeal request.

External advocacy resources. The Obesity Action Coalition (OAC) offers free appeal letter templates and will help patients understand state-specific step-therapy laws. The Patient Advocate Foundation also offers case management for insurance denials.

Manufacturer Savings Card and Other Cost Reduction Options

Novo Nordisk, the manufacturer of Saxenda, offers a savings card program for commercially insured patients. Eligible patients may pay as little as $25 per 30-day supply for up to 24 months. The savings card is not valid for patients covered by Medicare, Medicaid, TRICARE, or any other federal health program, consistent with federal anti-kickback statute requirements.

To use the savings card alongside Anthem coverage: the savings card typically applies after Anthem processes the claim, reducing the member's remaining cost-share. The pharmacy must be an in-network retail or mail-order pharmacy participating in the savings program.

For patients whose Anthem plan excludes anti-obesity drugs entirely, the savings card brings the $1,349 list price down to approximately $400 to $600 per month at participating pharmacies, depending on quantity. GoodRx and similar discount programs may further reduce cash-pay prices at specific pharmacy chains.

Telehealth-based weight-management programs may also be able to bill the behavioral counseling component to Anthem as a covered preventive service, reducing the total out-of-pocket spend on the combined program even when the drug itself is not fully covered.

Clinical Context: Why Saxenda Coverage Matters

Obesity affects approximately 41.9% of U.S. adults as of the most recent CDC National Health and Nutrition Examination Survey data. [6] Liraglutide 3 mg is one of only a handful of FDA-approved pharmacotherapies for chronic weight management with more than five years of post-marketing safety data.

The SCALE Maintenance trial (N=422) showed that patients who had lost at least 5% of body weight on liraglutide during a 12-week run-in period and then continued liraglutide 3 mg for 56 additional weeks maintained a mean weight loss of 6.2% from original baseline, compared to a regain that brought the placebo group to only 0.2% below baseline (P<0.001). [7] This discontinuation-and-regain pattern is the pharmacological rationale for long-term prescribing, and it is a key argument in a medical-necessity letter when Anthem imposes a 12-month coverage limit.

The 2023 American Heart Association Scientific Statement on obesity and cardiovascular disease explicitly recognizes GLP-1 receptor agonists as agents with demonstrated cardiovascular risk reduction in patients with type 2 diabetes. [8] For Anthem members with both obesity and established cardiovascular disease, citing this statement may strengthen the PA or appeal.

Saxenda is also FDA-approved for weight management in adolescents aged 12 to 17 with an initial body weight above 60 kg and obesity (defined by BMI at or above the 95th percentile for age and sex). [1] Anthem pediatric coverage policies differ from adult policies; the PA criteria often include additional documentation from a pediatric endocrinologist or obesity medicine specialist.

What to Expect After Approval

Once Anthem approves the PA, the authorization period is typically 12 months. Before renewal, the prescriber must document that the patient achieved at least 4% reduction in body weight by 16 weeks of treatment, consistent with the FDA label's titration and response guidance. [1] Patients who do not achieve this benchmark are considered non-responders, and Anthem may decline to renew the PA.

The dose titration schedule in the FDA label starts at 0.6 mg subcutaneously once daily for week 1, then increases by 0.6 mg each week until reaching the maintenance dose of 3 mg/day at week 5. [1] Documenting the titration in chart notes and confirming that the patient is on the full 3 mg dose before the 16-week weight check is important for avoiding a renewal denial based on inadequate dosing.

Common side effects including nausea, vomiting, diarrhea, and constipation are most prominent during titration. Patients who reduce the dose to manage side effects may not achieve the 4% weight-loss threshold, so proactive nausea management with dietary adjustments and timing of injection is worth documenting in the clinical record to support a renewal request if weight loss is borderline.